3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
3
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Disease Progression
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Lymphoma, Large B-Cell, Diffuse
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Etoposide
78
Carboplatin
67
Cisplatin
46
durvalumab
26
Topotecan
26
atezolizumab
20
Radiotherapy
19
Irinotecan
19
Paclitaxel
17
anlotinib
16
apatinib
15
Nivolumab
15
Drug Therapy
12
pembrolizumab
9
Platinum
9
toripalimab
8
tislelizumab
8
Gemcitabine
8
Bevacizumab
8
Temozolomide
7
Radiosurgery
7
PM 01183
7
Ipilimumab
7
Pemetrexed
6
Docetaxel
6
Albumin-Bound Paclitaxel
6
olaparib
5
amrubicin
5
Sunitinib
5
surufatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Small Cell Lung Carcinoma
×
tumor necrosis factor-alpha, CNGRC fusion protein, human
×
Clear all
NCT00483509
2019-10-04
NGR007
AGC Biologics S.p.A.
Phase 2
Completed
28 enrolled
10 charts